IDEMIA
IDEMIA Group announced today the appointment of Dominique Cerutti as Group Board Member, effective July 1st 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005297/en/
Dominique Cerutti comes with over 35 years of experience in Technology, R&D and Engineering services. He has held several CEO positions of leading technology companies and his expertise in growing large-scale international businesses will be a significant contribution to IDEMIA’s strategic vision.
“Dominique is a very seasoned leader with a demonstrated track record in transforming and growing large-scale international technology businesses. He will be instrumental for the Group moving forward”, said Pierre Barrial, IDEMIA Group President & CEO.
“We are pleased to welcome Dominique Cerutti to the IDEMIA Board. With more than 35 years of experience, Dominique is an undisputed expert in security and technology and a tremendous addition to IDEMIA’s Board” said Yann Delabrière, Chairman of the Board
“I couldn’t be more honored and thrilled to be joining IDEMIA, global leader in Augmented Identity, at an exciting time in its development. I look forward to offering strategic guidance and contributing to making the world a safer place”, said Dominique Cerutti.
NOTE TO EDITORS – Dominique Cerutti’s biography
Starting June 2015, Dominique Cerutti spent 5 years as Chief Executive Officer of the Altran group. He was also Chairman of the Altran Board from June 2015 to April 2020, until the acquisition of the company by Capgemini. Under his leadership, Altran has become the undisputed global leader in Engineering and R&D services, growing from 20,000 to more than 50,000 engineers worldwide, with revenues up to 3.2bn euros. He has deeply transformed the company by adapting the organization, promoting new business models and driving major acquisitions, enabling Altran to stay ahead of the competition, drive the market and reshape the global ER&D industry. Fervent advocate of the acquisition by Capgemini, he has worked hand in hand with the Group to make the integration a success and stepped down at the end of 2020.
Before joining Altran, Dominique Cerutti was CEO and Chairman of the Managing Board of Euronext, the leading pan-European exchange. He established Euronext as an independent company and the leading pan-European Exchange, through a successful IPO following the acquisition of NYSE-Euronext by the ICE Group in November 2013 and the subsequent demerger of Euronext from NYSE. He led the strategic repositioning of Euronext as the premier pan-European financing center. He and his team have been deeply involved with the correction of the previously biased EU financial markets regulation, promoting transparency and increased investors protections within the EU financial markets.
He was previously President and Deputy CEO, and a board member of New-York Stock Exchange (NYSE), the world’s leading exchange Group.
Dominique Cerutti also spent over 20 years at IBM in an international career, where he contributed to the company’s strategic transformation. In particular, he served as Chief Executive Officer of IBM Global Services for the Europe, Middle East, Africa, and later for IBM Europe, after being Executive Assistant to Lou Gerstner, Chairman and CEO of IBM.
He held various Board positions at LCH-Clearnet, Euromed Business School, New-York Stock Exchange, Altran, Euronext, Genes’ink.
Since March 2021, he is chairman of Adarma’s Board, one of the largest independent security services companies in the UK.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom